Tradestie Institutional Equity Comparison Engine
VCYT vs CGEN โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
CGEN Overall Edge
CGEN Captures Institutional Edge (3โ1 Pillars ยท 8โ2 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Compugen Ltd (CGEN) driven by superior Valuation, Growth & Margin, Momentum & Technical while VCYT counters with relative strength in Options & Structure. Fundamentally, VCYT trades at 15.5x Forward P/E with 15.0% operating margin (+15.1% YoY revenue) versus CGEN at 12.4x Forward P/E and 41.3% operating margin (+102.1% YoY). In options structure, VCYT sits in BREAKDOWN (9th %ile IV; Dealer Gamma Walls on Pro) against CGEN sits in BREAKDOWN (57th %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
CGEN
VCYT 15.5x vs CGEN 12.4x Fwd P/E
Growth & Margin Winner
CGEN
Op Margin 15.0% vs 41.3% ยท YoY +15.1% vs +102.1%
Momentum & Technical Winner
CGEN
1Y -38.4% vs +23.2% ยท 52W Pos 6% vs 33%
Options & Structure Winner
VCYT
BREAKDOWN (9th %ile IV) vs BREAKDOWN (57th %ile IV)
VCYT
NASDAQ
Veracyte, Inc.
Services-Medical Laboratories
$24.23
+0.92% 1D
Market Cap
$1.9B
1M Return
-44.68%
1Y Return
-38.42%
Forward P/E
15.5x
Unified AI Score
48.0 / 100
HOLD
Tech 55.0
Fund 56.0
Flow 57.0
Mom 55.0
CGEN
NASDAQ
Compugen Ltd
Biological Products, (No Diagnostic Substances)
$2.02
-0.98% 1D
Market Cap
$193.2M
1M Return
+2.54%
1Y Return
+23.17%
Forward P/E
12.4x
Unified AI Score
47.1 / 100
HOLD
Tech 44.0
Fund 52.0
Flow 54.0
Mom 64.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
VCYT -38.42%
CGEN +23.17%
Spread: +61.59 pp (CGEN Lead)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | VCYT Revenue | CGEN Revenue | VCYT Op. Margin | CGEN Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2018 | $90M | $20M | -24.2% | -130.5% | VCYT |
| FY2019 | $120M | N/A | -12.6% | N/A | VCYT |
| FY2020 | $120M | $0M | -30.1% | -1574.8% | VCYT |
| FY2021 | $220M | $10M | -37.3% | -584.6% | VCYT |
| FY2022 | $300M | $10M | -13.9% | -471.7% | VCYT |
| FY2023 | $360M | $30M | -23.8% | -38.8% | VCYT |
| FY2024 | $450M | $30M | 3.6% | -53.4% | VCYT |
| FY2025 | $520M | $70M | 11.2% | 43.1% | CGEN |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | VCYT | CGEN | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $1.9B | $193.2M | Larger Scale | VCYT |
| Trailing P/E Ratio Valuation | 15.6x | 5.2x | Lower Multiple | CGEN |
| Forward P/E Ratio Valuation | 15.5x | 12.4x | Lower Multiple | CGEN |
| Revenue Growth (YoY) Growth | +15.1% | +102.1% | Higher Growth | CGEN |
| Operating Margin (TTM) Profitability | 15.0% | 41.3% | Higher Margin | CGEN |
| Net Profit Margin Profitability | 21.8% | 47.9% | Higher Margin | CGEN |
| Return on Equity (ROE) Capital Efficiency | 9.4% | 57.2% | Higher ROE | CGEN |
| 52-Week Range Position Momentum | 6% ($22โ$61) | 33% ($1โ$3) | Stronger Trend | CGEN |
| Beta / 30D Volatility Risk Regime | 2.98ฮฒ ยท 194% Vol | 1.44ฮฒ ยท 62% Vol | Lower Realized Risk | CGEN |
| Unified Institutional Score Composite Signal | 48.0 / 100 (HOLD) | 47.1 / 100 (HOLD) | Higher Composite | VCYT |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full VCYT vs CGEN Buy Guide
VCYT
BREAKDOWN
100d in phase ยท OBV DISTRIBUTION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
9th %ile
IV Regime
Compressed (<25th %ile)
CGEN
BREAKDOWN
143d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
57th %ile
IV Regime
Balanced (25thโ60th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither VCYT nor CGEN registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.